Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ: TLSA ) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial. The ongoing study evaluates the company’s lead candidate, intranasal foralumab, designed as a treatment for Multiple System Atrophy (MSA). The latest data indicates a significant reduction in neuroinflammatory activity within disease-relevant brain regions following the completion of the dosing regimen. Consistent Imaging Results Across Trial Patients Quantitative analysis of the patient’s pre- and post-treatment PET scans showed notable decreases in radiotracer uptake. These improvements were localized in areas heavily impacted by MSA, specifically the cerebellar ...